The estimated Net Worth of Barbara Burnim Day is at least $846 Тысяча dollars as of 27 December 2005. Barbara Day owns over 14,500 units of Repligen stock worth over $846,060 and over the last 21 years Barbara sold RGEN stock worth over $0.
Barbara has made over 2 trades of the Repligen stock since 2005, according to the Form 4 filled with the SEC. Most recently Barbara exercised 14,500 units of RGEN stock worth $41,905 on 27 December 2005.
The largest trade Barbara's ever made was exercising 14,500 units of Repligen stock on 27 December 2005 worth over $41,905. On average, Barbara trades about 6,125 units every 31 days since 2004. As of 27 December 2005 Barbara still owns at least 5,900 units of Repligen stock.
You can see the complete history of Barbara Day stock trades at the bottom of the page.
Barbara's mailing address filed with the SEC is C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453.
Over the last 22 years, insiders at Repligen have traded over $118,224,292 worth of Repligen stock and bought 160,440 units worth $1,459,521 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Glenn P Muir и Walter C Herlihy. On average, Repligen executives and independent directors trade stock every 33 days with the average trade being worth of $3,015,702. The most recent stock trade was executed by Ralf Kuriyel on 2 August 2024, trading 7,148 units of RGEN stock currently worth $1,139,034.
repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.
Repligen executives and other stock owners filed with the SEC include: